Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Thursday, Needham analysts adjusted their stance on DENTSPLY SIRONA (NASDAQ:XRAY), downgrading the stock from Buy to Hold. The decision comes amidst discussions regarding a potential long-term slowdown in the dental market’s growth profile. Recent signs of weakening U.S. consumer sentiment have also contributed to the analysts’ outlook, leading them to predict that the dental market’s growth is unlikely to pick up in the near future.
DENTSPLY SIRONA, alongside Zimmer Biomet Holdings, Inc. (NYSE:ZBH), known by its ticker ZIMV, have both exhibited growth rates below that of the market. For ZIMV, currently trading at $12.65 near its 52-week low of $11.85, InvestingPro analysis suggests the stock is undervalued. Despite reporting losses in the last twelve months, analysts forecast a return to profitability with expected earnings of $0.86 per share in 2025. This underperformance, coupled with the absence of significant catalysts that might drive near-term multiple expansion, has led Needham to revise their ratings to Hold. The analysts no longer see a path for these stocks to outperform in comparison to their broader coverage universe.[Discover more insights with InvestingPro, including 6 additional ProTips and a comprehensive Pro Research Report that provides deep-dive analysis of ZIMV’s financial health, currently rated as FAIR.]
In addition to the downgrades, Needham analysts also offered insights on Align Technology , Inc. (NASDAQ:ALGN), specifically regarding the company’s exposure to tariffs. Align Technology, known for its Invisalign clear aligners, may face challenges related to international trade policies that could affect its cost structure and competitive positioning.
Furthermore, the analysts provided updates to their model for Envista Holdings Corporation (NYSE:NVST), following the company’s recent Capital Markets Day. Envista Holdings, a global family of more than 30 trusted dental brands, including Nobel Biocare and Ormco, may see adjustments to its financial forecasts based on the information shared during the event.
The downgrade reflects a cautious approach by Needham analysts towards the dental sector, especially in light of current economic indicators. DENTSPLY SIRONA’s stock performance will continue to be monitored alongside broader market trends and consumer confidence levels.
In other recent news, ZimVie Inc. reported its fourth-quarter 2024 earnings, with an earnings per share (EPS) of $0.27, surpassing the forecast of $0.26. However, the company faced a revenue shortfall, reporting $111.5 million against an expected $113.4 million. This mixed performance comes as ZimVie transitions to focus solely on dental products after divesting its spine business. The company experienced a 1.4% decline in revenue year-over-year, while its full-year revenue for 2024 was $450 million, marking a 1.6% decrease from the previous year. Despite these challenges, the company achieved a full-year adjusted EBITDA of $60 million, reflecting an 18% increase. Looking ahead, ZimVie projects 2025 revenue between $445 million and $460 million, with adjusted EPS expected to range from $0.80 to $0.95. Additionally, ZimVie’s leadership expressed optimism about achieving positive GAAP operating income in 2025, emphasizing their commitment to financial growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.